Pharmacological agents or ligands that produce analgesia.
. Currently available analgesics -nonsteroidal anti-inflammatory drugs (NSAIDs), amine reuptake inhibitors, anti epileptic drugs and opioids -have varying but typically low levels of analgesic efficacy, which is generally coupled with deleterious effects 2 . Indeed, opioids, which are the most commonly used (with ~240 million prescriptions in 2014 in the United States) 3 and often the most effective class of analgesics, produce tolerance, dependence and constipation, and are associated with major abuse liabilities. Furthermore, the respiratory depression associated with high doses has led to a catastrophic increase in the number of drug overdose deaths in the United States 3 (see the US Centers for Disease Control and Prevention website).
Diverse pathological situations at different anatomical sites can lead to pain. Causes of pain include cancer, inflammation or tissue injury, as well as injury or lesions of the nervous system 4-8 . Diverse chronic widespread pain syndromes may also occur owing to abnormal amplification states in the central nervous system (CNS) [9] [10] [11] . All of these can lead, through abnormal activity in nociceptive systems, to pain in the absence of a stimulus (spontaneous pain), exaggerated responses to noxious stimuli (hyperalgesia) and pain evoked by normally innocuous stimuli (allodynia).
The heterogeneity of clinical pain conditions and the complexity and multiplicity of underlying pathophysiological mechanisms has made it difficult to identify tractable targets with broad involvement -the blockbuster model of one treatment for all pain conditions is not tenable 12 . The poor predictability of preclinical 'pain' models can result in candidates being selected that do not have activity in the conditions suffered by patients 13
. Conversely, difficulty in ensuring target engagement, lack of sensitivity of clinical trials and distortions induced by placebos increase the risk that potentially effective compounds or targets may be prematurely abandoned 14, 15 . These issues have led to most drug developmental efforts being devoted to reformulations of existing validated analgesic classesopioids, NSAIDs, antiepileptic agents and amine reuptake inhibitors -despite their well-known limitations 16 . Given the prevalence of opioid diversion and overdose, there is an urgent need to develop effective and safe analgesics without a liability for abuse. Work from a large number of laboratories has shed light on the mechanisms and pathways that mediate specific aspects of the nociceptive nexus 8, 10, 11, [17] [18] [19] (FIG. 1) , revealing the potential for more fine-tuned targeting of acute and chronic pain in different clinical conditions. Completely new therapeutic strategies targeting ion channels, enzymes and G-protein-coupled receptors (GPCRs), often with human genetic validation, are emerging. In this Review, we present these emerging mechanisms and assess targets and agents in preclinical and early clinical stages of development that show promise for the development of innovative analgesics (TABLES 1, 2) .
Neurobiology of pain
The mechanisms that sustain and drive chronic pain (FIG. 1) have been exhaustively reviewed elsewhere 7, 10, 17, [20] [21] [22] [23] . In physiological situations, pain is a necessary protective response that is initiated by high-threshold peripheral sensory neurons to warn about the risk of harm by tissue injury or infection. Indeed, the presence of pain acts as a homing beacon to alert the body to the presence of a noxious stimulus so that necessary corrective responses can be mounted. For tissue injury and infection, pain hypersensitivity accompanies the associated inflammation and persists for the duration of the inflammatory response 17, 24 ; by encouraging the patient to avoid use of the affected body part, pain helps healing to occur. However, pain can also be maladaptive and pathological when it arises as a result of dysfunction of the nociceptive system, genetic factors (for example, paroxysmal extreme pain disorder caused by gain-of-function mutations in Nav1.7 (REF. 25)), injury to the nervous system that leads to neuropathic pain 17, 26 and abnormal central amplification syndromes. In all of these cases, pain is no longer the symptom but the disease itself.
Another driver for spontaneous pain in the absence of a peripheral stimulus is the ectopic activity of primary sensory neurons (FIG. 1) . Several voltage-gated sodium channels (Nav1.3 (REFS 27,28), Nav1.7 and Nav1.8 (REFS 29-34)), potassium channels (KCNQ), calcium channels (Cav2.2) and hyperpolarization-activated cyclic nucleotide-modulated channel (HCN) have been implicated in the modulation of ectopic activity and membrane excitability in sensory neurons, especially after peripheral nerve injury [35] [36] [37] [38] . However, a direct relationship between such ectopic activity of primary sensory neurons with spontaneous pain is yet to be proven, mainly due to inconsistent results and the paucity of reliable preclinical models, although live-cell imaging with genetically encoded activity reporters should change this.
One major consequence of peripheral inflammation is the hyperfunction of nociceptive transduction ion channels on the peripheral terminals of sensory neurons. These channels are responsible for converting noxious stimuli into inward currents. The peripheral sensitization of these transducers and ion channels involved in membrane excitability leads to a reduction in the threshold for activation and hyperexcitability of nociceptor sensory neurons 17 . However, peripheral sensitization alone does not fully account for the prolonged presence of pain, dynamic tactile allodynia, temporal summation of pain and the spread of pain hypersensitivity to non-injured tissue (secondary hyper algesia) 26 . These features of pain hypersensitivity are the consequence of augmented sensory signalling in the CNS due to a prolonged increase in excitability and synaptic efficacy of central nociceptive neurons and loss of inhibitory activity 26 . This phenomenon, called central sensitization, is common to all types of clinical pain, some of which are driven by activity in nociceptors as a form of activity-dependent plasticity, and some by autonomous changes in the CNS.
Several mechanisms contribute to central sensitization; increased synaptic strength due to an upregulation of presynaptic ion channels, increased presynaptic neuro transmitter release or enhanced postsynaptic neurotransmitter receptor activity 17, 26 . Disinhibition -in which inhibitory noradrenergic, opioid and GABAergic transmission is reduced through various synaptic changesand the loss of spinal interneurons also have a major role, especially in neuropathic pain 17, 26 . In addition, injury to the nervous system may produce structural changes in nociceptive circuits that lead to increased pain sensitivity. Depending on the underlying cause of pain, many of the above processes may also be acting in concert, further complicating treatment options 7 . In addition to the above mechanisms, there are multiple local and distributed pain modulatory influences. Endocannabinoids, for example, target cannabinoid receptors in both GABAergic and glutamatergic synapses, where they serve as retrograde transmitters and block the transmission of pain signals 39 . In addition, endogenous opioid peptides such as endorphins, enkephalins, dynorphin and endomorphins target the different opioid receptor subtypes (μ, κ and δ) to provide analgesia in various contexts [40] [41] [42] .
Box 1 | The challenges of preclinical models of pain
Preclinical rodent efficacy models are essential for analgesic development 255, 256 , but their predictive validity has been questioned owing to several high-profile programmes in which rodent behavioural readouts predicted analgesic effects that were absent in humans. For example, fatty acid amide hydrolase (FAAH) inhibitors were found to be antinociceptive in a range of animal models, but compounds such as PF-04457845 produced no analgesic effect in people with osteoarthritis despite lowering FAAH activity by >96% 244 . Similarly, NK1 (substance P) antagonists were shown to robustly reverse rodent nociceptive responses in the context of inflammation and nerve injury but failed to produce analgesia in subsequent clinical trials 257 . Nonetheless, many clinically used analgesics, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids, produce antinociceptive effects in rodents 256 , albeit typically at much higher doses than those used in patients.
Using animal models of pain to detect putative analgesics faces several challenges. First, how do you measure pain, a conscious subjective report of an unpleasant sensory experience, when you have no access to how an animal feels? Second, are the models true surrogates for the conditions or diseases that commonly produce pain in patients? Third, how do you eliminate the confounders of bias, observer-induced changes and lack of reproducibility? And last, it is possible that drugs that target human proteins may not be active on their rodent homologues.
Effectively measuring pain is perhaps the most difficult challenge, as we can only measure outcomes that may correlate with some aspect of pain, such as withdrawal from a stimulus or learned avoidance from a situation that may be painful. For reflexive measures of pain, typically a brief stimulus lasting for seconds is applied to a part of an animal's body and a response measured 5, 6 . This clearly bears little correspondence to the clinical situation of ongoing spontaneous pain. Attempts have been made to develop outcome measures that may reflect the presence of discomfort, but these require more effort and validation to make them robust and useful 255 . Some classes of analgesics, such as opiates, can reduce nociceptive reflexes at high doses; however, this does not mean that such reflexes have predictive validity for all classes of analgesics.
Some disease surrogates, such as pain in response to an acute noxious stimulus, incision wound or traumatic injury to a nerve, are easy to model 5, 6 . However, for chronic widespread pain, such as fibromyalgia, osteoarthritis and low back pain, there are no rodent models that phenocopy the human disease precisely.
Finally, a major difficulty with preclinical models is that the human observer may introduce changes in the animal's behaviour that may distort the outcome measure through induction of fear and anxiety 253 . Recently, even the gender of the investigator has been shown to have a significant impact on pain-related behaviour in mice 258 . Best laboratory practices can eliminate bias through thorough blinding, and independent replication should be standard 21, 22 . In conclusion, although preclinical models are invaluable for the validation of targets and the measurement of drug action, they currently lack predictive power, and findings must be interpreted with caution.
Central sensitization
A condition of the nervous system in which neurons in the central nervous system are in a state of prolonged increase in excitability and synaptic efficacy, coupled with the loss of inhibitory activity.
Analgesia
A lack of, or insensibility to, pain.
Nociception
Sensory neuronal responses to noxious or damaging stimuli that attribute the sensation of pain.
An often overlooked and underappreciated aspect of pain is that chronic pain can enhance negative emotional states along with comorbidities such as anxiety and depression 43, 44 . Analogously, studies have also shown that analgesia can be emotionally rewarding. The brain mesocorticolimbic region encodes reward and motivation, and the coupling of nociception to this region mediates pain aversion learning and memory 44 . The motivation to obtain pain relief can be very strong, and recent studies on the impact of chronic pain on reward and motivation circuits suggest that neurochemical changes in these brain regions may serve as objective markers for pain 44 .
Targeting the opioid system Exogenous opioid ligands isolated from opium poppy seeds have been used as potent analgesics for more than 3,000 years 41 , and opioids such as hydrocodone and morphine still remain the analgesics of choice for many physicians in the clinic. However, although targeting opioid receptors can lead to efficacious inhibition of pain, especially in an acute injury or palliative setting, opioid receptors also induce deleterious effects, such as tolerance, physical dependence and an addictive potential that has led to a crisis of prescription and recreational opioid abuse 45 . Numerous approaches are therefore being tested to mitigate the deleterious effects of opioid analgesics.
Abuse-deterrent opioids
Several companies have focused on modifying existing opioids to develop abuse-deterrent formulations (ADFs) 46, 47 . For example, extended release oxycodone (OxyContin; Purdue Pharma) and oxymorphone hydrochloride (Opana ER; Endo Pharmaceuticals) are commonly prescribed on the basis of the assumption that abuse only occurs with drugs that have rapid kinetics, which increases euphoria. However, this may be a misconception. The clinical data are scant and mostly inconclusive, but some data show that the incidence of abuse may actually increase with ADF opioids 46, 47 . Indeed, although formulated differently, the active agents are still euphoric opioids, and the drugs retain the potential side effects of the class, including the potential to overdose on high dose exposure 47 . In addition, although ADF OxyContin has reduced the number of prescriptions for and abuse of OxyContin 48, 49 , many abusers have either learnt to tamper with the abuse deterrence or have moved to other prescription opioids, such as fentanyl or heroin 50, 51 .
Peripherally restricted receptor ligands
All major opioid analgesics currently on the market are μ-opioid receptor agonists. Early efforts were made to develop κ-or δ-selective ligands because some of the initial selective compounds showed a lesser propensity There are several targets in peripheral neurons and in the nociceptive synapse between glia, peripheral nervous system neurons and central nervous system neurons in the spinal dorsal horn that provide interventional strategies for the development of analgesics. The central terminals of nociceptor sensory neurons synapse on neurons in the dorsal horn of the spinal cord, which, after processing by local circuits, relay the information to the brain. The presynaptic nociceptor terminals deliver input generated by noxious stimuli in the periphery, inflammation and peripheral nerve injury to the postsynaptic neurons. Several of the transmission and modulation mechanisms involved represent potential analgesic targets; excitatory transmissions could be reduced or inhibitory transmissions could be augmented. Some of the key players -opioids, cannabinoids, NK1 and other G-protein-coupled receptors (GPCRs) -are discussed throughout the main text, and others include ion channels such as NMDA (N-methyl-d-aspartate), AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) and GABA (γ-aminobutyric acid). Another key player is tyrosine kinase receptor A (TRKA; also known as NTRK1), which is targeted by nerve growth factor (NGF); NGF-TRKA-signalling blockade has been shown to produce potent analgesia. However, in many cases, a lack of specificity for nociceptive pathways makes on-target undesirable effects problematic. Cav, voltage-dependent calcium channel; CB 1 , cannabinoid receptor 1; CGRP, calcitonin gene-related peptide; Kv, potassium channel; mGluR, metabotropic glutamate receptor; Nav, sodium channel; P2X, purinoceptor; TRP, transient receptor potential cation channel. 
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Antinociception
Inhibition of sensory neuronal response to noxious stimuli that leads to reduction of pain sensation.
for physical dependence and abuse [40] [41] [42] . Indeed, many κ-agonists produce mild or severe aversive behaviour. However, such efforts have failed owing to ineffective analgesia (δ) or severe psychotomimetic and dysphoric effects (κ). For instance, κ-ligands such as enadoline and butorphanol were developed to have less abuse potential, but they are still rewarding, and also induce fatigue, sedation, confusion, anxiety, visual and auditory distortions and depersonalization 52, 53 . As many of the side effects of κ-agonists are generated in the CNS, Cara Therapeutics is currently developing a peripherally restricted κ-agonist, CR845, to be administered either intravenously or orally. Intravenous CR845 has been shown to successfully inhibit postoperative abdominal pain in phase II trials 54 , and an oral formulation is currently being tested in people with chronic knee pain in a phase II trial.
A recent study has reported an approach for targeting peripheral μ-opioid receptors without causing narcotic side effects. Painful conditions are often associated with localized tissue acidification. A fluorinated fentanyl analogue, NFEPP ((±)-N-(3-fluoro-1-phenethylpiperidin-4-yl)-N-phenylpropionamide), has been developed that, in contrast to the conventional opioid fentanyl, binds specifically to peripheral μ-opioid receptors in acidified peripheral tissues to provide antinociception without the side effects of respiratory depression, sedation, constipation or addiction potential 55 . These early preclinical and clinical data are promising, but questions still remain as to the efficacy of peripherally restricted ligands in reducing most forms of chronic pain, especially those sustained by central sensitization, as described above.
Heteromers, bivalent ligands and isoforms
Another approach to eliminate μ-opioid-associated side effects is based on burgeoning evidence that GPCRs, including opioid receptors, form both oligomers and higher-order complexes [56] [57] [58] (FIG. 2) . Homomers (complexes of similar receptors) and heteromers (complexes of different receptors) provide exciting potential targets for pharmacological intervention.
Several bivalent ligands have been generated that contain distinct pharmacophores for two receptors tethered together with a carbon atom linker of Cavs, voltage-gated calcium channels; Nav, voltage-gated sodium channel; TRPV1, transient receptor potential cation channel subfamily V member 1.
Ligand bias
Occurs when a ligand shows selectivity or preference to a particular signal transduction mechanism for a target receptor. Also called 'functional selectivity' .
varying lengths. These ligands demonstrate some promising pharmaco logical profiles (TABLE 1) . For example, MDAN-21 (μ-agonist-δ-antagonist) [59] [60] [61] [62] , a series of μ-agonist-cannabinoid receptor 1 (CB 1 ) antagonist ligands 63 , MMG22 (μ-agonist-metabotropic glutamate receptor 5 (mGluR5) antagonist) 64 and MCC22 (μ-agonist-C-C chemokine receptor type 5 (CCR5) antagonist) 65 have demonstrated potent antinociceptive activity in various preclinical rodent models of pain and are also devoid of tolerance or place preference, a measure of abuse liability. However, these molecules are rather large, raising questions about their bioavailability.
There is therefore interest in the development of small-molecule ligands for heteromeric opioid receptors. N-Naphthoyl-β-naltrexamine (NNTA), a selective agonist for μ-κ-opioid receptor heteromers, is an example 66 . μ-κ heteromeric opioid receptors have been found to form heteromers in the rat spinal cord, and there seems to be more of these receptors in female rats than in male rats 67 . NNTA targets μ-κ heteromers at subpicomolar concentrations and is a potent antinociceptive agent that does not seem to result in tolerance, physical dependence or drug-seeking behaviour in rodents 66 . NNTA is currently being investigated for safety by Blue Therapeutics through investigational new drug (IND)-enabling studies, and the company has plans for human clinical trials on successful filing of the IND package. The newly described buprenorphine small-molecule analogue BU08028 -a bifunctional ligand for μ and nociceptin opioid receptors -is another potential drug candidate that has displayed potent antinociception without concomitant respiratory depression or physical dependence in monkeys 68 . A different, but complementary, approach has focused on targeting different isoforms of the μ-opioid receptor (TABLE 1) . The opioid receptor mu 1 (Oprm1) gene has two independent promoters and can thus form several splice variants, including some unexpected six-transmembrane (6TM) domain receptors that are structurally quite different from 7TM domain GPCRs 69, 70 . For instance, the splice variant MOR1C results in a functionally active 6TM receptor, and the naltrexone derivative, iodobenzoylnaltrexamide (IBNtxA), that targets this receptor produces antinociception in mice without respiratory depression or drug-seeking behaviour in conditioned place preference studies 71, 72 . This suggests that the carboxy-terminal transmembrane domain of the μ-opioid receptor may not be necessary for the docking of certain ligands. Similarly, the modified C terminus of the functional splice variant MOR1D mediates its dimerization with gastrin-releasing peptide receptor (GRPR) to generate opioid-induced itch in mice, providing further evidence that the MOR C terminus may have a key role in producing adverse effects of opioids 73 . Several questions remain, however, as to how these truncated receptors signal, the extent and level of tissue expression, and why targeting them alters μ-opioid side effects. In addition, further research is warranted to determine the similarity between human and murine opioid receptor isoforms.
Biased ligands
GPCRs were initially considered to signal only through the specific G proteins that they couple with, but the recent discovery of ligand bias has enhanced our understanding of GPCR signal transduction and provided new GPCR pharmacology 74 . GPCR coupling with β-arrestins can be promoted or avoided by ligands that restrict the receptor to particular conformations, and can thus lead to several distinct pharmacological outcomes from the same receptor [75] [76] [77] [78] [79] [80] [81] [82] (FIG. 2) .
Several biased agonists have been developed targeting opioid receptors that produce reduced opioid side effects with similar or better antinociception, at least Nature Reviews | Drug Discovery 
Biased GPCR signalling GPCR dimerization
Psychotomimetic effects
A state of psychosis of the mind leading to delusions, hallucinations, and so on that are precipitated by a pharmacological agent or ligand.
Post-herpetic neuralgia
Pain caused by nerve damage due to infection with varicella zoster virus.
in preclinical animal models 74, 83 (TABLE 1) . A prominent example is oliceridine (TRV130; Trevena), a μ-opioid receptor biased agonist that activates G-protein signalling, but not β-arrestin. Clinical trials with TRV130 have been largely positive, showing that it is well tolerated and has comparable analgesic efficacy to morphine but with a faster onset 84, 85 . TRV130 also produces significantly reduced respiratory depression, nausea and vomiting in patients; however, this seems to be dose-dependent 84 . The fact that respiratory depression is not completely eliminated with this approach is concerning, as the abuse liability of this compound has not yet been determined in humans.
The recent exciting discovery of PZM21 -a G i -biased μ-opioid agonist -clearly illustrates that differential pharmacology can be achieved by selectively activating specific signalling messengers through the same receptor 86 . The compound is the product of extensive in silicoassisted screening of >3 million ligands and is devoid of the common opioid side effects of constipation, respiratory depression and drug-seeking behaviours. However, some questions remain as to the analgesic efficacy of the molecule, as it was found to be four times less potent than morphine in rodent studies 73 .
Non-opioid GPCRs
Outside the opioid receptor system, a few other receptors have been found to be directly involved in pain pathways, including cannabinoid receptors, angiotensin type 2 receptor and α2 adrenergic receptors.
Cannabinoid receptors
The cannabinoid receptors, CB 1 and CB 2 , have been intensively investigated as targets for potential pain therapeutics 87 . Whereas CB 1 receptor agonists produce severe psychotomimetic effects and have a large abuse potential, selective CB 2 agonists produce analgesia in preclinical models without any major CNS side effects 87, 88 . CB 2 receptors were initially thought to be peripherally restricted targets, but they are expressed in the CNS (FIGS 1,2), especially by spinal microglia and interneurons. Many pharmaceutical companies have developed selective CB 2 agonists, but initial clinical trials failed owing to lack of efficacy 87, 89 . However, Arena 
Angiotensin type 2 receptor
Another intriguing GPCR, angiotensin type 2 receptor (AT 2 R), belongs to the renin-angiotensin system, which is now recognized as contributing to neuropathic pain in preclinical rodent models 90, 91 . Whereas AT 1 R has a major role in hypertension, AT 2 R is expressed in human sensory neurons and, when activated, sensitizes transient receptor potential cation channel subfamily V member 1 (TRPV1) ion channels that mediate thermal pain 92, 93 . Although the mechanism by which AT 2 R inhibitors reduce neuropathic pain remains unknown, the inhibition of p38 and extracellular-signal-regulated kinase-mitogen-activated protein kinase (ERK-MAPK) pathways has been implicated 90, 94 . Spinifex Pharmaceuticals has developed a highly selective AT 2 R inhibitor, EMA401, that inhibits capsaicin-induced calcium fluxes in human and rat dorsal root ganglia (DRGs) and produces dose-dependent anti nociception in mouse neuropathic pain models, effects that are abolished in AT 2 R-null mice 90 (TABLE 1) .
Phase I and II clinical trials have shown that EMA401 is well tolerated and produces significant analgesia with daily dosing in people suffering from post-herpetic neuralgia 92 . However, by contrast, a mycobacterial polyketide mycolactone has been shown to activate AT 2 R to induce analgesia in mice with Buruli ulcer 95 . The fact that both activators and antagonists of the same receptor produce analgesia complicates the delineation of the mechanism of action of AT 2 R in pain.
α2 adrenergic receptors Studies of the role of the α2 adrenergic system in pain are conflicting. Pharmacological studies and studies in null mice show that α2 receptors seem to play a part in diverse painful syndromes by inhibiting the presynaptic release of neuropeptides in the spinal cord and acting on microglia [96] [97] [98] [99] [100] . However, pontine α2 adrenergic activation increases pain by attenuating descending inhibition 101 . A meta-analysis of 28 clinical trials found that although intraoperative administration of the α2 adrenergic receptor agonist dexmedetomidine (DEX) reduced post operative pain and opioid consumption, and lowered the risk of opioid-related adverse effects, some patients suffered from intraoperative bradycardia, and the postoperative administration of DEX did not have significant effects on pain management 102, 103 . Recro Pharma is developing an intranasal DEX formulation (DEX-IN) that is administered at one-eighth to one-tenth of the intravenous recommended dose, which could reduce adverse effects. In phase II trials, DEX-IN produced positive efficacy results for treatment of postoperative (bunionectomy) pain, but likewise generated adverse Figure 2 | Peripheral analgesic drug discovery targets. The peripheral terminals of primary afferent nociceptor neurons express G-protein-coupled receptors (GPCRs) and various ion channels that mediate the transduction of different sensory modalities, some of which have specific coupling and signalling features that offer opportunities for novel drug classes. GPCRs can utilize both G proteins and β-arrestins as secondary messengers, and biased ligands can engage particular signalling pathways to obtain increased efficacy and reduced adverse effects. GPCRs can also form complexes with other receptors, leading to the formation of homomers or heteromers. Furthermore, they functionally interact with ion channels such as transient receptor potential cation channel subfamily V member 1 (TRPV1), TRPA1 and G-protein-activated inward rectifier potassium channels (GIRKs). Anti-nerve growth factor (NGF) antibodies have also been developed with the intent of alleviating certain pain modalities by blocking the activation of tyrosine kinase receptor A (TRKA). In addition, inhibitors for sodium channels (Nav) and calcium channels (TRP and voltage-gated calcium channels (VGCCs)), and potassium channel openers have been developed with intriguing pharmacology. Ligands for some of these targets that are currently in analgesic clinical trials are shown. NNTA, N-naphthoyl-β-naltrexamine
Symptoms such as anxiety and shaking that develop on cessation of a drug that has been used repeatedly.
effects that are characteristic of α2 adrenergic agonists, including reduced blood pressure and bradycardia. Plans for phase III trials of DEX-IN for postoperative pain are pending US Food and Drug Administration (FDA) input (see DEX-IN phase II efficacy press release and DEX-IN phase II side effects press release).
Chemokine receptors
Pro-inflammatory chemokines contribute to chronic inflammatory pain 104 . Chemokines modulate nociceptors through the activation and sensitization of sodium and TRPV1 channels and also communicate between immune, neuronal and glial cells [105] [106] [107] . The injection of certain chemokines leads to pain 106, 107 , whereas chemokine antagonists produce antinociception 108 . However, given the numbers of these signalling molecules and their importance in immune function 109 , chemokines are challenging therapeutic targets.
There seems to be some crosstalk between opioid and chemokine pathways -especially in the context of opioid tolerance, opioid withdrawal-induced hyperalgesia and opioid-induced hyperalgesia. This crosstalk may reflect hetero-desensitization and heterooligomerization between opioid and chemokine receptors [110] [111] [112] [113] . Co-administration of morphine with C-X-C motif chemokine 12 (CXCL12; also known as SDF1), C-X3-C motif chemokine 1 (CX3CL1; also known as fractalkine) or C-C motif chemokine 5 (CCL5) leads to reduced opioid analgesia in rodents [114] [115] [116] [117] [118] . Conversely, administration of antibodies to CCL2 or a CXCR4 inhibitor (plerixafor (AMD3100; Mozobil; Genzyme)) leads to reduced opioid-induced hyperalgesia and tolerance in rodents 115, 119 . Bivalent ligands for μ-CCR5 heterooligomers show potent antinociception without any tolerance, dependence or abuse potential in mice 65 . However, clinical trials with chemokine antagonists have not been successful. AZD2423 (AstraZeneca), a selective CCR2 antagonist, effectively reduced neuropathic pain in rodent models but did not produce analgesia in people with post-herpetic neuralgia 120 . Species differences or poor CNS activity may have led to this failure, and dual-targeting antagonists such as RAP-103 (Rapid Pharmaceuticals; a CCR2-CCR5 dual antagonist) are under development with the aim of achieving a better efficacy profile 121 .
Ion channels as drug targets
Ion channels underlie all electrical activity by neurons. In principle, targeting ion channels to disrupt pain signalling could be done at all stages, from inhibiting the firing of primary nociceptors to inhibiting second-or higher-order neurons in the spinal cord and brain. The most obvious way of selectively targeting pain signalling is to target ion channels that have preferential expression in primary nociceptors. This is the strategy embodied in drugs targeted to TRPV1 channels, which are strongly expressed in primary nociceptors and have little or no expression in most other neuronal types 122 . Several other potential drug targets, including Nav1.8 and Nav1.9 voltage-dependent sodium channels, are also highly expressed in primary nociceptors with little expression in other neuronal types, whereas Nav1.7 sodium channels are expressed in a wider variety of peripheral sensory and sympathetic neurons but have little expression in the CNS 123, 124 . Although current strategies have focused on channels in primary sensory neurons, there is potential to target ion channels in higher-order neurons. In this case, it would be difficult or even impossible to confine drug effects only to nociceptive pathways. However, this is not necessarily an insurmountable problem. Many existing ion channelbased therapies for other conditions are also targeted to channels with wide expression in the nervous system, including anti-epileptic drugs targeted broadly to sodium channels and anxiolytic drugs targeted to γ-aminobutyric acid type A (GABA A ) channels 16 . In general, our knowledge of the organization of neurons and neuronal circuits is too primitive to understand how such drugs targeted to widely expressed ion channels can achieve clinical efficacy without debilitating side effects. As we gain more detailed knowledge about the patterns of expression, regulation and function of various channels in higher-order pain signalling neurons, it may be possible to target the activity of these neurons in a rational manner.
TRPV1 channels
The molecular cloning of TRPV1 channels and their identification in 1997 as a receptor in primary sensory neurons mediating thermal pain 125 (FIG. 1) led to an avalanche of studies implicating TRPV1 activation in various preclinical pain models. Drug development programmes targeting TRPV1 channels followed quickly, with patents filed for more than 1,000 compounds by approximately 50 companies 126 . So far, the results have been disappointing. In general, the efficacy of TRPV1 antagonists in clinically relevant pain conditions in humans has been modest, and there are two problematic adverse on-target effects seen with many of the compounds: reduced sensitivity to noxious heat, potentially leading to accidental burns, and an increase in body temperature, probably reflecting the participation of TRPV1 channels in normal temperature regulation [126] [127] [128] . These issues, along with modest efficacy, have resulted in the discontinuation of most programmes.
However, recent work suggests that it may be possible to develop compounds that retain anti-nociceptive activity without adverse effects. This would require agents that can inhibit the activation of TRPV1 channels by endo genous ligands that mediate pain but that do not inhibit the activation of TRPV1 channels in response to increases in temperature or low pH (which has been suggested to mediate the control of body temperature 129 ). Such 'modality-specific antagonists' are based on evidence that vanilloid ligands such as capsaicin (and perhaps endogenous agents mediating pain) activate TRPV1 in a different way from temperature or pH, and that these modalities of activation can be differentially inhibited [128] [129] [130] . NEO6860 (Neomed) is one such modality-specific agent 131 and is currently in phase II trials for osteoarthritis. New technology that can provide high-resolution structures of ligand-bound TRPV1 channels using cryo-electron microscopy 132, 133 should greatly facilitate further development of this approach 128 .
Trigeminal neuralgia
A painful condition caused by disease affecting, dysfunction of or damage to the trigeminal nerve.
Anosmia
Loss of the sense of smell.
Sodium channels
Voltage-dependent sodium channels underlie electrical signalling in all neurons. There are nine distinct types of sodium channels encoded by different genes, of which three (Nav1.1, Nav1.2 and Nav1.6) are widely expressed in both the CNS and peripheral nervous system (FIG. 2) and three more (Nav1.7, Nav1.8 and Nav1.9) are expressed mainly in subsets of peripheral neurons. Currently used sodium channel blockers, including lidocaine, amitriptyline and mexiletine, display relatively little selectivity among different sodium channels, and their therapeutic window is limited by unwanted side effects, mainly from actions on the CNS. This has stimulated efforts to develop compounds that are selective for the sodium channels with little expression in the CNS. Nav1.7. Nav1.7 channels are expressed in nociceptors and sympathetic neurons, with only low expression in the CNS 123, 134 . They emerged as prime candidates for novel analgesics following the identification of rare human mutations in which loss of function in Nav1.7 channels resulted in congenital insensitivity to pain 135, 136 . In addition, a number of gain-of-function mutations in Nav1.7 have been identified, in which patients experience pain, sometimes severe, either spontaneously or triggered by normally innocuous stimuli 124 . Similarly, mouse knockout models of Nav1.7 show nearly complete insensitivity to nociceptive stimuli and loss of inflammatory pain, whereas the mice respond normally to various non-painful stimuli [137] [138] [139] . Nav1.7 is currently being actively pursued by the pharmaceutical industry. Potent small-molecule inhibitors of Nav1.7 channels have been found [140] [141] [142] , most notably a class of sulfonamide compounds that can be made highly selective for Nav1.7 channels over other sodium channels, and even selective for human Nav1.7 channels over those from other species 143 . Clinical trials of several of these compounds are underway (TABLE 2) , including the Icagen/Pfizer compound PF-05089771, which completed phase II trials for wisdom tooth removal and primary erythromelalgia 144 , and two compounds (GDC-276 and GDC-0310) developed by Xenon Pharmaceuticals, which are being tested in phase I trials in collaboration with Genentech 145 . The binding site for sulfonamide inhibitors has recently been determined and is completely different to that of classic small-molecule sodium channel blockers such as lidocaine, carbamazepine and other local anaesthetics and anti-epileptic agents, which interact with the pore region of the sodium channels and generally have little selectivity among different sodium channel subtypes 146, 147 . The high specificity of sulfonamide compounds and the unusually detailed knowledge of their binding site should allow the design of even more potent and selective small-molecule Nav1.7 inhibitors.
Several non-sulfonamide-class compounds that are targeted primarily to Nav1.7 channels, but are generally less selective, are also being tested. Raxatrigine (Convergence/Biogen) has been tested in phase II trials in trigeminal neuralgia 148 , and funamide (TV-45070, Xenon/ Teva), is in phase IIb trials for post-herpetic neuralgia 149 .
In addition, peptide inhibitors of Nav1.7 channels have been developed by cleverly modifying naturally occurring peptides from spider venom. This approach exploits amino-acid differences among different sodium channel types in extracellular loops of the channel proteins and has yielded peptide inhibitors with very high affinity for blocking Nav1.7 channels and a high degree of subtype selectivity 150 . However, the delivery of these large peptide compounds may present a substantial challenge for clinical translation. A potential problem with the clinical use of Nav1.7 blockers is that although the channels are minimally expressed in the CNS, they are expressed in primary olfactory neurons 151 , meaning that a potent Nav1.7 blocker may well produce anosmia, a side effect that has been found intolerable by a substantial fraction of patients in clinical trials of drugs with other targets.
Another potential issue relates to the recent finding that sensitivity to pain can be restored by naloxone in both Nav1.7-null mice and in a human lacking Nav1.7 (REF. 152 ). This raises the possibility that the loss of pain sensation in null mutants is more complicated than simple functional removal of Nav1.7 channels and may result from upregulation of opioid pathways inhibiting pain. However, it is possible that such upregulation reflects complex compensatory events during development that would not be mimicked by acute inhibition. Nav1.8. Nav1.8 channels are tetrodotoxin (TTX)-resistant, voltage-gated sodium channels that are expressed in small-diameter primary nociceptive neurons, with little or no expression in other neuronal types. In principle, their selective expression and dominant contribution to the overall sodium current in smalldiameter DRG neurons (at least in the soma) make Nav1.8 channels attractive as drug targets. Moderately selective Nav1.8 inhibitors have been developed and have exhibited anti-nociceptive properties in rodent models 30, 153 . There have been efforts to develop Nav1.8 inhibitors for clinical use in humans 140 . However, the only reported clinical test of a Nav1.8-selective inhibitor, the Pfizer compound PF-04531083 (REF. 154 ), resulted in a terminated trial on dental pain, and there is no evidence of other efforts 120 . Although Nav1.8 channels are prominent in the cell bodies of nociceptive DRG neurons, axonal propagation in these neurons generally depends on TTX-sensitive channels 32, 155 . In a rat model of neuropathic pain, expression of Nav1.8 in axons is sufficiently upregulated to allow TTX-resistant propagation of action potentials in some C fibres 32 , but it remains unclear under what conditions Nav1.8 inhibition can inhibit the generation or propagation of action potentials in human pain conditions. Nav1.9. In a similar way to Nav1.8 channels, Nav1.9 channels are expressed in small-diameter primary nociceptive neurons. Nav1.9 channels activate and inactivate very slowly, and under normal physiological conditions they seem to be mostly inactivated. Their normal physio logical function may be to provide a small current to help depolarize the resting potential and amplify slow subthreshold depolarizations between the resting potential and spike threshold 156 . Nav1.9-knockout mice exhibit normal sensitivity to acute pain but reduced hyperalgesia in response to inflammation, suggesting that these channels may represent therapeutic targets 157 . Screening for blockers of Nav1.9 has been hampered by the inability to express Nav1.9 in heterologous systems, although an expressible chimeric Nav1.9-Nav1.4 channel has recently been reported 158 .
Targeted delivery of charged sodium channel blockers. An alternative strategy for targeting Nav1.7 or Nav1.8 channels is to use large-pore channels that are selectively expressed by primary pain-initiating nociceptor neurons as portals for delivering drugs (FIG. 2) . Many primary nociceptors express either TRPV1 channels or transient receptor potential cation channel subfamily A member 1 (TRPA1) channels, or both. These channels are unusual in that they form a pore that allows the entry of very large cations 159 , including N-methyl-d-glucamine (195 Da) 160 and the cationic dye FM1-43 (MW 452 Da) 161 . This property can be exploited to deliver cationic drug molecules into the neurons. The lidocaine derivative QX-314 (N-ethyl-lidocaine) is a cationic molecule (263 Da) that is ineffective in inhibiting neuronal sodium channels when presented on the extracellular side of the channel because it is too large to enter the sodium channel pore from the outside; however, it can enter and inhibit channels when presented on the intracellular side [162] [163] [164] . Such entry occurs only when channels are open and the QX-314 molecule can be trapped inside the channels when the channel closes again, so the blocking effect accumulates in a use-dependent manner. The pores of both TRPV1 and TRPA1 channels are large enough for QX-314 to permeate into the cell [162] [163] [164] , with entry of the cationic molecule driven not only by the concentration gradient but also by the negative intracellular membrane voltage, promoting higher concentrations inside the cell. Thus, externally applied QX-314 can enter and inhibit sodium channels in neurons when TRPV1 or TRPA1 channels are activated 162, 164 . Some P2X family channels, including P2X purinoceptor 2 (P2X2), P2X4 and P2X7, also have large pores and can probably admit QX-314 and similar molecules [165] [166] [167] . In initial experiments studying perineural application to sciatic nerves in normal animals, QX-314 co-applied with capsaicin produced long-lasting inhibition of pain signalling with little effect on motor function mediated by the same nerve trunk 162, 168, 169 . In later experiments, QX-314 was co-applied with lidocaine, which acts as an agonist at both TRPV1 and TRPA1 channels at millimolar concentrations 170, 171 . Lidocaine blocks all nerve function but only transiently (~1 hour), whereas co-application with QX-314 produced noci ceptive block lasting up to 9 hours or more 168, 169 , probably reflecting long residency of QX-314 after it has entered TRPV1-and TRPA1-containing fibres.
In many clinical situations, TRPV1 and TRPA1 channels may be sufficiently activated endogenously that there is no need to apply an exogenous TRP channel activator along with the cationic sodium channel blockers. For example, during itch, TRPV1 or TRPA1 channels are activated by second messengers whose release is triggered by various GPCRs 172 . Activation of these receptors is sufficient to facilitate QX-314 inhibition of experimentally induced itch 172 . During inflammation, TRPV1 and TRPA1 channels are activated by endogenous agents, and in this circumstance it is likely also unnecessary to co-apply an exogenous TRP channel activator. Moreover, because the activation of C fibres and release of neuropeptides is often part of the inflammatory process, inhibiting C-fibre electrical activity can actually reduce inflammation, not just block the pain or itch resulting from the inflammation. C-Fibre silencing by entry of charged sodium channel blockers can reduce airway inflammation in animal models of asthma 146 . A limitation of this strategy is that the cationic sodium channel blockers must be applied in close proximity to the nerve fibres being silenced, because as cationic molecules they have limited tissue penetration. Suitable application methods include direct instillation into wounds, local injections and delivery by aerosol to affect lung inflammation. Application to broken skin in dermatitis or similar conditions could also be effective. Notably, this limited tissue penetration means that there is little or no systemic exposure of the cationic agents, greatly minimizing the chance of unwanted effects.
Calcium channels
Voltage-dependent calcium channels (Cavs) are calcium-selective channels that are closed at normal resting potentials and opened by depolarization. They underlie many neuronal functions, including helping to regulate cellular excitability and mediating the release of synaptic vesicles. Of ten voltage-dependent calcium channels encoded by the mammalian genome, eight have wide expression in neurons.
The most widely used current therapeutic agents targeting voltage-dependent calcium channels are gabapentin (Neurontin; Pfizer) and pregabalin (Lyrica; Pfizer), which are thought to act by affecting the trafficking and recycling of calcium channel proteins 147, 173 . For treating hyperalgesia and neuropathic pain, gabapentin and pregabalin are effective in only a minority of patients, and the reasons for this are still unknown. It has been proposed that improved therapeutic selectivity might be attained by agents that are selective for α2δ1 subunits, as these subunits seem to mediate the antihyperalgesic effects of gabapentin and pregabalin. However, in addition to α2δ1 subunits, gabapentin and pregabalin bind α2δ2 subunits, which may mediate side effects 173 . Furthermore, recent advances in our understanding of a couple of calcium channels have opened up some additional avenues for analgesic drug design.
Cav2.2 splice variants.
Synaptic transmission is triggered by calcium entry through presynaptic calcium channels. Most synaptic transmission in the mammalian brain and spinal cord is mediated by Cav2.1 (P/Q-type) and Cav2.2 (N-type) calcium channels 173, 174 . Interestingly, transmission at the first synapses in the pain pathway, glutamatergic synapses from primary sensory neurons to second-order neurons in the dorsal horn, seems to rely nearly exclusively on presynaptic Cav2.2 channels. Cav 2.2-knockout mice have reduced sensitivity to some but not all types of acute, inflammatory and neuropathic pain (reviewed in REF. 37 ). Cav2.2 channels can be blocked selectively by several peptides from the venom of cone snails; one of these, ω-conotoxin MVIIA, also known as ziconitide (Prialt; Elan Pharmaceuticals), is currently used to treat pain, with application by intrathecal pump. However, its utility is limited by a small therapeutic window, probably reflecting the participation of Cav2.2 channels in other functions of the spinal cord and perhaps spillover of peptide into higher regions of the nervous system.
The efficacy of Prialt has stimulated efforts to find small-molecule inhibitors of Cav2.2 channels that could be effective against pain. Several such inhibitors have been reported, including TROX-1 (REFS 175, 176) . Like most small-molecule sodium channel inhibitors, these are state-dependent inhibitors, which bind more tightly to activated states of the channel than resting, closed states. Therefore, state-dependent inhibition results in greater inhibition of channels that are repetitively cycling quickly through activated states, potentially conferring at least some selectivity for neurons that are hyperactive. Although several such state-dependent calcium channel inhibitors have demonstrated effective pain relief in several rodent models [175] [176] [177] , efficacy in human trials remains to be demonstrated.
As Cav2.2 channels are widely expressed in the brain, a systemically available channel blocker that crosses the blood-brain barrier would probably exhibit serious unwanted effects. However, the Cav2.2 channels in primary sensory neurons have different splice variants from the predominant channels in the brain (reviewed in REF. 178 ), raising the possibility of developing small molecules with sufficient selectivity to reduce spinal cord transmission without deleterious central effects.
Cav3.2 channels. Cav3.2 channels are low-threshold T-type channels that in various central neurons can mediate burst firing after hyperpolarization (which removes resting inactivation of the channels). Their normal physiological function in sensory neurons is enigmatic, but knockout of Cav3.2 channels or knockdown by antisense RNA has an impressive analgesic effect on mechanical and thermal pain in rats 179, 180 , raising the possibility that they could be targeted therapeutically. The AbbVie compound ABT-639, an orally available Cav3.2 inhibitor with reasonable selectivity, produced dose-dependent antinociception in a rat model of kneejoint pain and reduced tactile allodynia in several rodent models of neuropathic pain, including spinal nerve ligation and chronic constriction injury (CCI) 181 . However, subsequent clinical trials of ABT-639 with human volunteers showed no effect in an acute intradermal capsaicin pain model in which pregabalin was effective 182 . Similarly, ABT-639 did not reduce pain in patients with diabetic neuropathy 183 . Other Cav3.2 inhibitors have been described to be effective in pain models, including a rat model of pain from irritable bowel syndrome 184 . Several molecules that have state-dependent blocking activity at both Cav2.2 and Cav3.2 channels (and variable potency for blocking other calcium channels such as Cav2.1) have been described and reported to be effective in rat models of neuropathic pain, inflammatory pain and mechanical allodynia [185] [186] [187] . However, whether related compounds are being pursued for possible clinical use is unclear.
Potassium channels
Mammalian neurons express many different types of potassium channels, with significantly different expression patterns among various types of neurons. A number of different potassium channels are downregulated in primary sensory neurons in animal models of hyperalgesia and neuropathic pain 38, [188] [189] [190] [191] [192] [193] , probably contributing to consequent hyperexcitability of pain-signalling neurons. In principle, enhancing current through potassium channels could be an effective way of inhibiting neuronal activity, and the differential expression patterns of various types of potassium channel offers the possibility of inhibiting the activity of a specific neuronal population, such as nociceptors, without excessive disruption of other neuronal functions 194 . The search for enhancers of potassium currents to inhibit pain signalling is relatively recent, but already it is evident that the general strategy may be promising 195, 196 . So far, the most attention for this approach has been on Kv7 (KCNQ) family channels 35, [197] [198] [199] , and several members of the 'two-pore' (K2P) family of channels 188, 200 . An alternative approach to small-molecule enhancers of channel function is to attempt to correct the changes in potassium channel gene expression that are associated with pain 191 . Kv7 channels. Kv7 channels are voltage-dependent channels that typically activate and deactivate relatively slowly and often can be activated by small subthreshold depolarizations. The original description of a neuronal Kv7 current was 'M-current' , named after its ability to be inhibited by muscarinic stimulation in sympathetic neurons and later shown to be mediated by Kv7.2-Kv7.3 heteromeric channels 201 . By activating slowly with small depolarizations, Kv7 current produces strong adaptation of firing evoked by steady depolarization. Kv7.2-Kv7.3 channels seem to be widely expressed in the nervous system, often with strong expression at the axon initial segment, where they are well positioned to modulate action potential firing 202, 203 . A number of compounds have been found that enhance the activation of Kv7 family channels by shifting the voltage-dependence of activation to more negative voltages. The best known of these is retigabine (Trobalt; GlaxoSmithKline), which was introduced for use as an anti-epileptic drug. Retigabine inhibits nociceptive behaviours in rodent models of neuropathic pain 204, 205 and hyperalgesia 36 . Whether the effects are mediated by central or peripheral neurons is unclear. Disappointingly, however, a clinical study on human neuropathic pain failed to meet its primary efficacy end point (NCT00612105), adding retigabine to the long list of compounds with efficacy in rodent models of pain that seem to have much less dramatic effects in humans. Another compound that enhances Kv7 channelmediated current by shifting activation to more negative voltages is flupirtine (Katadolon; Asta Medica), which is
Allosteric modulators
Ligands that alter the activity of an agonist, antagonist or inverse agonist of a target by binding to a site distinct from the active site.
in the same chemical class as retigabine (differing only by substitution of a pyridine ring for a phenyl ring). Interestingly, flupirtine was introduced to clinical practice as a centrally acting non-opioid analgesic in Europe in 1984. The effects of flupirtine may be mediated centrally and/or peripherally. Small-diameter DRG neurons probably corresponding to C fibres express Kv7.2 subunits, and a component of their potassium current is inhibited by the Kv7 blocker XE991 (REF. 206 ). Knockout of Kv7.2 in all somatic sensory neurons produces a modest enhancement of withdrawal from painful mechanical and thermal stimuli, mediated primarily by loss of Kv7.2 from Aδ fibres 207 , perhaps reflecting the prominent expression of Kv2 channels in nodes of Ranvier of many myelinated nerves. Of particular interest, the primary Kv7 subunit expressed by small-diameter C-fibre nociceptors is Kv7.5 (REF. 208 ), raising the possibility that screening for selective enhancers of this subunit might identify novel peripherally acting analgesics. However, Kv7.5 is also prominently expressed in vascular smooth muscle, so such agents may also decrease blood pressure. But if the channels in C-fibre nociceptors are Kv7.5 homomers and those in vascular muscle are heteromers with other Kv7 subunits, there may be an opportunity for selective targeting.
K2P channels. Two-pore-domain (K2P) family channels constitute a diverse group of 15 gene products. Each protein contains four transmembrane segments and two pore domains, with channels formed by dimers of subunits 209 . K2P channels are widely expressed in both neurons and non-neuronal cells. Many K2P channels are constitutively open, and K2P channels underlie the main resting potassium conductance that is responsible for the negative resting potential of cells. Because of their regulation of both resting potential and input conductance of neurons, K2P channels can exert strong control over neuronal excitability. For that reason, compounds that enhance the opening of K2P channels (or perhaps upregulate their expression) are an attractive possibility for drug development. Compared with many other channels, there is relatively little known about the functional contributions of specific K2P channels in various neuronal types, largely because there are currently few specific pharmaco logical tools. Nevertheless, recent findings suggest that several K2P channels could be attractive clinical targets for pain relief. A number of K2P channels expressed in DRG neurons are downregulated after nerve injury and in various other animal models of neuropathic pain associated with neuronal hypersensitivity 210 . Of particular interest is TREK1 (also known as KCNK2) on the basis of the striking finding that it can be activated by morphine through μ-opioid receptors; the analgesic action of morphine in TREK1-knockout animals is reduced by about half 211 . Currently, too little is known about relative expression of various K2P channels in different neuronal (and nonneuronal) types to predict which might be the best targets for pain relief while minimizing the disturbance of other functions. The development of specific pharmacological tools, which is underway in several laboratories 212, 213 , should be a key step.
Kv2-Kv9 channels. Kv2 channels are voltage-activated delayed rectifier potassium currents that are widely expressed in both peripheral and central neurons. Kv2.1 subunits have especially wide and high expression in many neuronal types. A particularly interesting property in regards to possible drug development is that Kv2 subunits can make heteromeric channels with subunits from other gene families, including Kv5, Kv6, Kv8 and Kv9 subunits -these so-called 'silent' subunits do not seem to make functional channels on their own 214, 215 . In the context of pain, attention has been focused particularly on Kv9.1 subunits, for which a common human allelic variant is strongly associated with increased susceptibility to neuropathic pain 6 . Subsequent animal studies showed that Kv9.1 subunits are strongly downregulated in primary sensory neurons after nerve injury, in parallel with the development of pain behaviours 216 . The reduction of Kv9.1 expression is hypothesized to produce spontaneous firing of Aδ fibres 210, 216, 217 . Thus, a plausible pharmacological strategy would be to find small-molecule enhancers of Kv2.1-containing channels, either targeted to remaining Kv2.1-Kv9.1 channels or to whatever heteromeric combinations are favoured after downregulation of Kv9.1. Kv2.1 channels are also strongly expressed in small-diameter C-fibre DRG neurons, where they are potentially associated with various other silent subunits, including Kv6.1, Kv8.1, Kv9.2 and Kv9.3 (REF. 218 ). The potential for Kv2-based channels made by highly diverse combinations of subunits in different neuronal types raises the possibility of finding small molecules with differential selectivity for particular subunit combinations that could preferentially reduce the excitability of pain-signalling neurons. The possibility of pharmacological selectivity targeted to different subunit combinations is validated by differential sensitivity to the broad-spectrum inhibitor 4-aminopyridine 219 , but this has not yet been systematically explored.
Ion channels in higher-order neurons
In neuropathic pain, there is likely to be altered excitability and circuitry of higher-order nociceptive neurons in the spinal cord and brain. Little is known about the ion channels involved in controlling changes in the excitability of higher-order neurons, but as our understanding increases, it may be possible to selectively target such activity. Agents such as amitryptiline that reduce sodium channel activity broadly, without subtype selectivity, could act in pain relief by modifying the activity of higher-order neurons as well as primary sensory neurons (FIG. 1) .
Discussion of the mechanism of action of gabapentinoids has generally focused on synaptic transmission at first-order synapses in the spinal cord, as their effects on the trafficking of calcium channels have been studied in DRG neurons 147 , but such effects could also occur at higher-order synapses. Positive allosteric modulators of GABA A chloride channels could have potential as pain relievers 220, 221 , but generally they also produce strong sedation. It was recently found that flupirtine enhances GABA-mediated currents at concentrations comparable to those enhancing Kv7 activity 222 . GABA A channels are highly diverse in terms of subunit structure, being pentameric combinations of 19 different potential subunits, and they are found in different combinations in different neurons and subcellular regions -the reasons for which are incompletely understood. Thus, it may be possible to find agents with selectivity for specific subunit combinations that enhance pain-relief properties relative to sedation 223 . A better understanding of the expression patterns of specific GABA A receptor subunit combinations in the higher-order neuronal pain-mediating circuitry would be useful for a rational approach in this direction.
Enzymes as analgesic drug targets
NSAIDs, the most widely used analgesics, target the enzyme cyclooxygenase (COX), and there is growing interest in targeting other enzymes for analgesic development (TABLE 3) .
BH 4 synthesis: sepiapterin reductase
Axonal injury increases the production of tetrahydrobiopterin (BH 4 ) from GTP in injured neurons owing to increased expression of GTP cyclohydrolase 1 (GCH1), the rate-limiting enzyme in the BH 4 pathway, in the injured cells 224 . BH 4 is an essential cofactor for aromatic amine hydroxylases, nitric oxide synthases and alkylglycerol monooxygenase. Nerve injury is also accompanied by increased BH 4 synthesis in the macrophages that infiltrate proximal to the injury 225 . Human genetic studies reveal an association between GCH1 polymorphisms that decrease BH 4 levels and reduced pain in patients. Furthermore, decreasing BH 4 levels by inhibiting or knocking out GCH1 in sensory neurons produces analgesia in rodents 224, 225 . Inhibition of GCH1 does, however, create a risk of adverse effects in the nervous and cardiovascular systems owing to decreased synthesis of biogenic amines and nitric oxide if BH 4 falls excessively below basal levels. An alternative strategy to minimize the risk of side effects is targeting sepiapterin reductase (SPR), the terminal enzyme in the BH 4 synthetic pathway, blockade of which allows enough BH 4 production through the BH 4 salvage pathway to prevent adverse effects while nevertheless reducing the increased levels that contribute to neuropathic and inflammatory pain 225 . SPR inhibition produces analgesia in multiple acute and chronic neuropathic and inflammatory pain models with no tolerance and no effect on acute nociception 225 . One attractive feature of SPR inhibition for drug development is that target engagement can be determined by measuring sepiapterin levels in plasma; sepiapterin can be used as a biomarker of efficacy for the reduction in BH 4 levels 225 . Interestingly, a yeast three hybrid screen using drugs with clinical activity but no known target led to the discovery that sulfasalazine, an FDA-approved drug that is used to reduce inflammation and its associated pain in rheumatoid arthritis and inflammatory bowel disease, inhibits SPR, although with very low potency 226 . Quartet Medicine, through a strategic partnership with Merck, is developing novel SPR inhibitors for the treatment of neuropathic and inflammatory pain.
Microsomal prostaglandin E2 synthase 1
Microsomal prostaglandin E 2 synthase 1 (mPGES1) is responsible for prostaglandin E 2 (PGE 2 ) production during inflammation as the terminal enzyme in the prostanoid pathway, acting downstream of COX2 (REF. 227 ). PGE2 is a major inflammatory sensitizer of nociceptors, and mPGES1 inhibition using 229 . EpFAs act as upstream modulators of endoplasmic reticulum stress pathways, which are engaged in diabetic neuropathy and whose reduction leads to analgesia 230 . However, because some EETs sensitize nociceptors 231 , sEH inhibition is likely to increase inflammatory pain 232 . This would probably complicate the development of these inhibitors as analgesics, as inflammatory and neuropathic pain may coexist.
Proteases
Several proteases -serine proteases (trypsin), matrix metalloproteinases (MMPs), cysteine proteases (cathepsin S), caspases and proteinase-activated receptor 2 (PAR2) -have been implicated in pain modulation [233] [234] [235] [236] . Increased levels of serine proteases and PAR2 have been observed in mice with cancer pain, which is attenuated by inhibition of protease levels or completely eliminated in mice that are deficient in PAR2 (REF. 233 ). Transient increases in MMP9 levels and delayed but persistent increases in MMP2 levels have been shown to induce and maintain neuropathic pain in rodents 234 . The same study also showed that MMP inhibitors can produce antinociception, suggesting that MMPs may be a target for developing therapeutics. It should be noted, however, that MMPs are also involved in several other pathways, and broad-spectrum inhibitors can cause toxic side effects. Indeed, clinical trials with MMP inhibitors for cancer have failed as a result of toxicity and lack of efficacy. Similarly, both caspase 6 and cathepsin S have been shown to regulate neuronal-glial interactions during neuropathic pain and potentially lead to central sensitization 235, 236 . Serine protease inhibitor A3N (Serpin A3N), an endogenous serine protease inhibitor, is upregulated in injured sensory neurons after axonal injury and seems to protect against neuropathic pain in those animals where the degree of upregulation is high 237 .
Mice lacking Serpin A3N develop more mechanical allodynia after nerve injury than wild-type mice, and exogenous delivery of Serpin A3N attenuates mechanical hyper sensitivity 237 . Serpin A3N inhibits leukocyte elastase (also known as neutrophil elastase) which is released by the T lymphocytes that infiltrate the DRG after nerve injury. Genetic loss of leukocyte elastase or administration of the leukocyte elastase inhibitor sivelestat (Elaspol; Ono Pharmaceuticals) has been shown to attenuate mechanical allodynia in neuropathic models 237 . These findings reveal complex crosstalk between injured sensory neurons and immune cells, and identify a novel immune cell target for further evaluation as an analgesic for neuropathic pain.
Challenges and considerations
The assessment of failure in proof-of-principle efficacy clinical trials for novel analgesics is commonly beset by insufficient reporting by industry. Consequently, it is often uncertain whether the wrong target, drug, outcome measure or patient was selected. It is also unclear whether there was a failure of target engagement or too strong a placebo response. If nothing is learned from these phase II trials, it is cumulatively an enormous waste of resources, and some drugs may be prematurely abandoned.
Particularly worrying is the possibility that preclinical models are not true surrogates of human disease and that reflexive-stimulus-evoked 'pain' measurement may not be a sensitive predictor of efficacy in patients
. In many cases, adverse effects mean that it is simply not possible to achieve in humans the drug exposure levels that are required in animals to show efficacy. In addition, a large placebo effect and emotional control of pain, among other reasons, further complicate analgesic clinical trial design
. Some of the key challenges in assessing novel analgesic action are illustrated by recent pain trials exploring novel 'pain' targets.
Predictive failure of preclinical models Rodents, especially mice, remain the preclinical model organism of choice for the validation of targets and the testing of their ligands, typically using pain-related behavioural measures. Because many neurobiological and disease mechanisms and pathways are evolutionarily conserved, much useful information can be gleaned by using wild-type or genetically modified animals. However, major problems remain. First, there is considerable debate as to the relevance of reflexively evoked responses to noxious stimuli to clinical pain conditions, especially spontaneous pain and changes in cognitive function and mood. Second, many of the pain models are not good surrogates of human disease (BOXES 1,2) . Inflaming or damaging a joint, for example, does not make a good model of osteoarthritis. Below are two examples in which preclinical efficacy could not be replicated in human clinical trials.
Propentofylline. The glial-modulating agent propentofylline failed in a study conducted by Solace Pharmaceuticals to decrease pain in people with post-herpetic neuralgia, despite some activity in rodent peripheral neuropathic models. The likely explanation for this failure could be a major species difference between rodents and humans, both in microglial activation and in propentofylline action 238 . The involvement of microglia and astrocytes in pain in humans remains to be tested, and the failure of propentofylline indicates the importance both of human target validation, most commonly by genetics, and of drug action on human cells. p38 pathway inhibitors. The p38 MAPK inhibitor losmapimod exhibited no efficacy in people with neuropathic pain from lumbosacral radiculopathy, despite preclinical studies showing the involvement of p38 signalling pathways in the development of persistent pain after peripheral nerve injury 239 . It is uncertain whether the trial failed because of a lack of adequate target engagement or differences between chronic (conditions lasting for years) lumbosacral radiculopathy and much more acute (conditions lasting for days or weeks) animal models of neuropathic pain 240 . Because the preclinical data were not aligned with the patient cohort tested, the significance of the failed trial for other pain types is uncertain, which is true for most neuropathic pain trials. However, p38 activation is downstream of nerve growth factor (NGF), a validated target for novel analgesics (see below) and for angiotensin, which seems to act in the periphery to block TRPV1 sensitization 90 . Notably, an AT 2 R antagonist, EMA401, has efficacy in post-herpetic neuralgia 92 , representing the first drug acting on a novel target to show efficacy in neuropathic pain for some time. At the time that EMA401 was tested, its analgesic mechanism of action was uncertain 94, 241 . TRPV1 antagonists, however, have had to be abandoned because of on-target hyperthermia 242 .
Achieving CNS penetration
Many of the targets relevant to pain are expressed in the CNS. However, developing analgesics that are capable of penetrating the CNS is a significant challenge. The blood-brain barrier prevents ligands of certain chemical structures from effectively penetrating the CNS and reaching their targets. In addition, after compounds enter the brain, they may be actively pumped out by various efflux pumps 243 . Cannabinoid agonists (CB 1 ) have major actions in humans, including claims of analgesia 87, 88 . However, the clinical use of CB 1 agonists or cannabis is complicated by the drug abuse liability from psychoactive effects; therefore, increasing the level of endogenous endocannabinoids represents an attractive alternative strategy. The endocannabinoids anandamide and 2-arachidonoylglycerol, acting at CB receptors, are metabolized by hydrolytic enzymes (fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL)) and by oxygenating enzymes (COX2). However, an irreversible fatty acid amide hydrolase 1 inhibitor, PF-04457845, failed to reduce pain from osteoarthritis of the knee, despite decreasing FAAH activity by >96% and substantially increasing fatty acid amide endogenous substrates; furthermore, many preclinical studies showed the efficacy of the drug in models of inflammatory pain 244 . Whether the lack of effect of PF-04457845 on pain reduction represents an inability to access FAAH in the CNS remains unknown. Despite this failure, other FAAH inhibitors are entering clinical trials 245, 246 , and there is preliminary human genetic support for FAAH involvement in cold pain sensitivity 247 .
Adverse effects
Although chronic pain can be debilitating and can reduce quality of life, in several clinical conditions ongoing pain protects damaged tissue from further insult. For example, anti-NGF antibodies (tanezumab, fulranumab and fasinumab) have, surprisingly, proven to be more efficacious in people with osteoarthritis than would be expected from the preclinical data 248 , achieving greater efficacy than that of the standard of care (NSAIDs and opioids) for chronic low back pain, osteoarthritis and diabetic neuropathy [249] [250] [251] . However, tanezumab resulted in the rapid progression of osteoarthritis, particularly when administered at high doses and with NSAIDs 252 . Although the cause of this is uncertain, one possibility is that the overuse of damaged joints because of high analgesia coverage may lead to accelerated joint destruction. Additional concern comes from the role of NGF as a growth factor in development. In pregnant cynomolgus monkeys, intra venous tanezumab increased stillbirth and infant mortality, and decreased infant growth with changes in the peripheral sympathetic and sensory nervous system including developmental neurotoxicity 149, 144 .
Box 2 | Pain clinical trial design
Phase II proof-of-concept clinical trials for novel analgesics are beset by a number of major problems: how to measure the pain, how to differentiate placebo from drug effect and how to select patients. Pain is a subjective experience that is influenced not only by heritable traits but also by psychosocial processes, culture, experience, social and biological context, and mood 259 . Translating this dynamic complex internal experience into verbal descriptors and numerical or analogue scales of intensity may not capture comparable levels of sensation between or within subjects, even with training 260 , and certainly does not reflect the degree or nature of the precipitating initiator or maintainer of the pain. In addition, the high level of placebo and nocebo responders in chronic pain trials is a major confounder 261 . Attempts are being made to deal with bias and unreliability, most notably by ACTTION (Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks) 16 , a public-private partnership with the US Food and Drug Administration. Trial design can be improved by better diagnostics, blinding and choice of primary outcome measure, adaptive designs, crossovers and random withdrawal, use of adequate power and responder analyses 262 . However, there is a lack of predictive biomarkers, either of pain or of target engagement, which makes it difficult to understand the underlying pathophysiology that leads to various clinical presentations of pain and whether a drug is having any action, although new imaging technology may change this 263 . Although preclinical pain research has evolved into classifying different types of pain on the basis of mechanism, little of this has translated into pain diagnosis in the clinic 12 . Recent studies have proposed several ways to approach this issue: a successive classification methodology can be used to identify the pain state, pain mechanism and molecular target in sequence, emphasizing the development of individualized therapy or precision medicine 12 ; clinically relevant patient clusters can be identified on the basis of pathophysiological mechanisms 254 ; and, similarly, patients can be matched on the basis of phenotypic characteristics that are predictive of individual variation 264 . These proposals are a first effort to classify clinical pain in a fashion that lends itself to improved clinical trial design and to meaningful pharmacological intervention, where efficacy can be readily identified and quantified.
Conclusions: the road ahead There are several promising emerging targets for the treatment of acute and chronic pain. However, the key question is still whether preclinical efficacy data will translate to humans, and if not, why not. Although high-throughput screening in heterologous cell lines generates selective ligands, the lack of normal pathways that affect the target of interest in its native cellular environment may lead to the selection of suboptimal ligands. In this context, phenotypic screens performed directly in human neurons differentiated from patient induced pluripotent stem cell lines may help in greatly enhancing the quality of patient-relevant data 133, 145 . A similar argument exists for many of the commonly used reflexive-avoidance pain behavioural models in rodents
. Given that rodents are prey animals, their behaviour can be highly influenced by environment and investigator 253 . Together, these issues suggest that we need to make a considerable effort to develop assays that can measure spontaneous pain automatically and model human disease conditions as closely as possible
Finally, focusing on targets such as Nav1.7 that already have human genetic data supporting their involvement in pain may provide less risky opportunities to develop new effective analgesics than a reliance on rodent-based models of pain. However, studies should not be restricted only to targets with human genetic data, as many targets of the most widely clinically used drugs would not have been selected on the basis of genetic variants producing clear disease-related phenotypes. In addition, large, rare phenotypes, such as insensitivity to pain, may not be useful for identifying targets engaged in clinical conditions, such as after damage to the nervous system or in response to chronic inflammation.
Despite this, combinations of phenotypic screens in patient-derived neurons, human genetics, genome editing in mice and human cell lines, as well as improvements in drug design and kinetics, the identification of biomarkers and clinical trial design
, offer an increasing probability of success. As new therapeutic opportunities arise from such efforts, they may enable a precision-medicine approach in which treatment can be targeted at the particular mechanisms driving pain in individual patients 254 . This review highlights common misconceptions about abuse-related liabilities of prescription opioids and proposes strategies that could help to mitigate these risks.
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Phenotypic screens
Unbiased screening strategies in which the functional output is a pre-determined alteration of phenotype.
